BioXcel Therapeutics, Inc. Increase (Decrease) in Inventories
BioXcel Therapeutics, Inc. (BTAI) reported Increase (Decrease) in Inventories of -$239.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-13
- BioXcel Therapeutics, Inc. increase (decrease) in inventories for the quarter ending 2026-06-30 was -$17.00K.
- BioXcel Therapeutics, Inc. increase (decrease) in inventories for the quarter ending 2026-03-31 was -$222.00K.
- BioXcel Therapeutics, Inc. increase (decrease) in inventories for the quarter ending 2025-12-31 was $263.00K.
- BioXcel Therapeutics, Inc. increase (decrease) in inventories for the quarter ending 2025-09-30 was -$47.00K.
- BioXcel Therapeutics, Inc. increase (decrease) in inventories for fiscal 2025 was $43.00K.
- BioXcel Therapeutics, Inc. increase (decrease) in inventories for fiscal 2024 was -$1.31M, a 21966.67% decline from fiscal 2023.
- BioXcel Therapeutics, Inc. increase (decrease) in inventories for fiscal 2023 was $6.00K, a 99.70% decline from fiscal 2022.
- BioXcel Therapeutics, Inc. increase (decrease) in inventories for fiscal 2022 was $1.99M.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$239.00K 10-Q · filed 2026-08-13 | $24.00K derived: sum of 3 quarters · filed 2026-08-13 | -$23.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$222.00K 10-Q · filed 2026-05-15 | $41.00K derived: sum of 2 quarters · filed 2026-05-15 | -$6.00K derived: sum of 3 quarters · filed 2026-05-15 | -$142.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $263.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $216.00K derived: sum of 2 quarters · filed 2026-03-27 | $80.00K derived: sum of 3 quarters · filed 2026-08-13 | $43.00K 10-K · filed 2026-03-27 |
| 2025-09-30 | -$47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$183.00K derived: sum of 2 quarters · filed 2026-08-13 | -$220.00K 10-Q · filed 2025-11-12 | -$1.07M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$136.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$173.00K 10-Q · filed 2026-08-13 | -$1.02M derived: sum of 3 quarters · filed 2026-08-13 | -$2.17M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$37.00K 10-Q · filed 2026-05-15 | -$883.00K derived: sum of 2 quarters · filed 2026-05-15 | -$2.04M derived: sum of 3 quarters · filed 2026-05-15 | -$1.80M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$846.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$2.00M derived: sum of 2 quarters · filed 2026-03-27 | -$1.76M derived: sum of 3 quarters · filed 2026-03-27 | -$1.31M 10-K · filed 2026-03-27 |
| 2024-09-30 | -$1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$914.00K derived: sum of 2 quarters · filed 2025-11-12 | -$466.00K 10-Q · filed 2025-11-12 | -$493.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $241.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $689.00K 10-Q · filed 2025-08-12 | $662.00K derived: sum of 3 quarters · filed 2025-08-12 | $755.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $448.00K 10-Q · filed 2025-05-12 | $421.00K derived: sum of 2 quarters · filed 2025-05-12 | $514.00K derived: sum of 3 quarters · filed 2025-05-12 | $487.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $66.00K derived: sum of 2 quarters · filed 2025-03-28 | $39.00K derived: sum of 3 quarters · filed 2025-03-28 | $6.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $93.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $66.00K derived: sum of 2 quarters · filed 2024-11-14 | $33.00K 10-Q · filed 2024-11-14 | $610.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$60.00K 10-Q · filed 2024-08-06 | $517.00K derived: sum of 3 quarters · filed 2024-08-06 | $530.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$33.00K 10-Q · filed 2024-05-09 | $544.00K derived: sum of 2 quarters · filed 2024-05-09 | $557.00K derived: sum of 3 quarters · filed 2024-05-09 | $1.27M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $577.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $590.00K derived: sum of 2 quarters · filed 2024-03-22 | $1.30M derived: sum of 3 quarters · filed 2024-03-22 | $1.99M 10-K · filed 2024-03-22 |
| 2022-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $726.00K derived: sum of 2 quarters · filed 2023-11-14 | $1.41M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $713.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.40M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $682.00K 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |